PMID- 31709050
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 2050-0068 (Print)
IS  - 2050-0068 (Electronic)
IS  - 2050-0068 (Linking)
VI  - 8
IP  - 11
DP  - 2019
TI  - Idiopathic and immune-related pulmonary fibrosis: diagnostic and therapeutic 
      challenges.
PG  - e1086
LID - 10.1002/cti2.1086 [doi]
LID - e1086
AB  - Interstitial lung disease (ILD) encompasses a large group of pulmonary conditions 
      sharing common clinical, radiological and histopathological features as a 
      consequence of fibrosis of the lung interstitium. The majority of ILDs are 
      idiopathic in nature with possible genetic predisposition, but is also well 
      recognised as a complication of connective tissue disease or with certain 
      environmental, occupational or drug exposures. In recent years, a concerted 
      international effort has been made to standardise the diagnostic criteria in ILD 
      subtypes, formalise multidisciplinary pathways and standardise treatment 
      recommendations. In this review, we discuss some of the current challenges around 
      ILD diagnostics, the role of serological testing, especially, in light of the new 
      classification of Interstitial Pneumonia with Autoimmune Features (IPAF) and 
      discuss the evidence for therapies targeted at idiopathic and immune-related 
      pulmonary fibrosis.
CI  - (c) 2019 The Authors. Clinical & Translational Immunology published by John Wiley & 
      Sons Australia, Ltd on behalf of Australian and New Zealand Society for 
      Immunology Inc.
FAU - McLean-Tooke, Andrew
AU  - McLean-Tooke A
AUID- ORCID: 0000-0003-4307-0837
AD  - Department of Clinical Immunology Sir Charles Gairdner Hospital Perth WA 
      Australia.
AD  - Department of Laboratory Immunology PathWest QEII Medical Centre Perth WA 
      Australia.
FAU - Moore, Irene
AU  - Moore I
AD  - Department of Respiratory Medicine Fiona Stanley Hospital Perth WA Australia.
FAU - Lake, Fiona
AU  - Lake F
AD  - Department of Respiratory Medicine Sir Charles Gairdner Hospital Perth WA 
      Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20191105
PL  - Australia
TA  - Clin Transl Immunology
JT  - Clinical & translational immunology
JID - 101638268
PMC - PMC6831929
OTO - NOTNLM
OT  - connective tissue disease
OT  - diagnosis
OT  - interstitial lung diseases (ILDs)
OT  - pulmonary fibrosis
OT  - therapeutics
COIS- IM has received funding to attend an educational meeting from Boerigher 
      Ingelheim, the manufacturers of nintenadib. AMT and FL declare no conflicts of 
      interest.
EDAT- 2019/11/12 06:00
MHDA- 2019/11/12 06:01
PMCR- 2019/11/05
CRDT- 2019/11/12 06:00
PHST- 2019/04/17 00:00 [received]
PHST- 2019/09/29 00:00 [revised]
PHST- 2019/10/10 00:00 [accepted]
PHST- 2019/11/12 06:00 [entrez]
PHST- 2019/11/12 06:00 [pubmed]
PHST- 2019/11/12 06:01 [medline]
PHST- 2019/11/05 00:00 [pmc-release]
AID - CTI21086 [pii]
AID - 10.1002/cti2.1086 [doi]
PST - epublish
SO  - Clin Transl Immunology. 2019 Nov 5;8(11):e1086. doi: 10.1002/cti2.1086. 
      eCollection 2019.